Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID

BACKGROUND: Immunocompromised patients have varying responses to SARS-CoV-2 mRNA vaccination. However, there is limited information available from prospective clinical trial cohorts with respect to long-term immunogenicity-related responses in these patient groups following three or four vaccine dos...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Puran, Bergman, Peter, Blennow, Ola, Hansson, Lotta, Mielke, Stephan, Nowak, Piotr, Söderdahl, Gunnar, Österborg, Anders, Smith, C.I. Edvard, Vesterbacka, Jan, Wullimann, David, Cuapio, Angelica, Akber, Mira, Bogdanovic, Gordana, Muschiol, Sandra, Åberg, Mikael, Loré, Karin, Sällberg Chen, Margaret, Buggert, Marcus, Ljungman, Per, Aleman, Soo, Ljunggren, Hans-Gustaf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365982/
https://www.ncbi.nlm.nih.gov/pubmed/37453361
http://dx.doi.org/10.1016/j.ebiom.2023.104700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365982/
https://www.ncbi.nlm.nih.gov/pubmed/37453361
http://dx.doi.org/10.1016/j.ebiom.2023.104700

Ejemplares similares